Pharmafile Logo

thinkemotive

- PMLiVE

Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial

Trial will evaluate donanemab in participants at risk for cognitive and functional decline related to Alzheimer’s

Realizing the Potential of Genomics-Driven Precision Medicine

Jennifer Helfer, Senior Director, Patient Advocacy & Engagement at Encoded Therapeutics Inc., discusses genomics-driven precision medicine, gene therapy misconceptions and fears, involving patients and caregivers in designing gene therapy trials,...

Impetus Digital

Helping Patients Become Active Participants in Their Own Care

Rishi Nayyar, Co-founder & CEO of PocketHealth, explores how releasing medical imaging records straight to patients can result in data moving more ethically, easily, and securely. He also shares his...

Impetus Digital

- PMLiVE

Ogilvy Health appoints Rebecca Carter to newly created head of social media role

Three new hires have also joined the dedicated healthcare communications team

Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network

The network, called EmerGENE, combines experts from Ashfield Health, Ashfield Engage and Ashfield Advisory

- PMLiVE

UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med

Three of the ten companies named in CMA’s statement said they disagreed with the decision and would be appealing against the fines

- PMLiVE

AZ, J&J to research modifications to COVID-19 vaccines over rare blood clot issues

Researchers to explore potential of modifications to vaccine to reduce or remove risk of rare blood clots

- PMLiVE

British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura

PMI, which owns a portfolio of tobacco products, announced a deal to acquire Vectura for £927m earlier this week

Virtual Speaker Program: A Customer Story

Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions.

Impetus Digital

- PMLiVE

Eli Lilly to acquire Protomer Technologies in a deal worth over $1bn

Protomer Technologies is a US biotech company focused on engineering glucose-responsive insulin

- PMLiVE

FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm

Leaders maintain that Aduhelm fits into the regulatory paradigm of the FDA’s accelerated approval pathway

- PMLiVE

FDA questions safety profile of AZ, FibroGen’s anaemia drug roxadustat

AZ and FibroGen are aiming for approval of roxadustat in anaemia caused by chronic kidney disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links